Skip to main content

Articles

Page 33 of 76

  1. In the publication of our publication [1], we have noticed there is a wrong label in Fig. 1e, in which the position of “HCC” and “Adjacent” should be transposed.

    Authors: Wuhua Zhou, Li Gong, Qinchuan Wu, Chunyang Xing, Bajin Wei, Tianchi Chen, Yuan Zhou, Shengyong Yin, Bin Jiang, Haiyang Xie, Lin Zhou and Shusen Zheng
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:445

    The original article was published in Journal of Experimental & Clinical Cancer Research 2018 37:215

  2. In the original publication of this article [1], the indicated stages (I-II III-IV) were missing in the clinical stage part at both Table 1 and Table 2.

    Authors: Kai Teng, Shi Wei, Chi Zhang, Jiewei Chen, Jinbin Chen, Kanghua Xiao, Jun Liu, Miaomiao Dai, Xinyuan Guan, Jingping Yun and Dan Xie
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:442

    The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:329

  3. In the original publication of this article,[1] the Funding section needs to be revised, and the corrected Funding section appears below.

    Authors: Morvarid Saeinasab, Ahmad Reza Bahrami, Jovanna González, Francesco P. Marchese, Dannys Martinez, Seyed Javad Mowla, Maryam M. Matin and Maite Huarte
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:441

    The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:172

  4. In the original publication of this article [1], there are mistakes in Fig. 4d. The corrected Fig. 4 should be:

    Authors: Sahyun Pak, Sejun Park, Yunlim Kim, Jung-Hyuck Park, Chan-Hee Park, Kyoung-June Lee, Choung-soo Kim and Hanjong Ahn
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:440

    The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:342

  5. ERp57 dysfunction has been shown to contribute to tumorigenesis in multiple malignances. However, the role of ERp57 in clear cell renal carcinoma (ccRCC) remains unclear.

    Authors: Yan Liu, Jian-Xing Wang, Zi-Yuan Nie, Yue Wen, Xin-Ju Jia, Li-Na Zhang, Hui-Jun Duan and Yong-Hong Shi
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:439
  6. Glutathione S-transferase zeta 1 (GSTZ1) is the penultimate enzyme in phenylalanine/tyrosine catabolism. GSTZ1 is dysregulated in cancers; however, its role in tumorigenesis and progression of hepatocellular c...

    Authors: Jingjing Li, Qiujie Wang, Yi Yang, Chong Lei, Fan Yang, Li Liang, Chang Chen, Jie Xia, Kai Wang and Ni Tang
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:438
  7. All-trans-retinoic-acid (ATRA) is a promising agent in the prevention/treatment of breast-cancer. There is growing evidence that reprogramming of cellular lipid metabolism contributes to malignant transformati...

    Authors: Mineko Terao, Laura Goracci, Valentina Celestini, Mami Kurosaki, Marco Bolis, Alessandra Di Veroli, Arianna Vallerga, Maddalena Fratelli, Monica Lupi, Alessandro Corbelli, Fabio Fiordaliso, Maurizio Gianni, Gabriela Paroni, Adriana Zanetti, Gabriele Cruciani and Enrico Garattini
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:436

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2019 38:496

  8. Our previous work demonstrated that lncRNA-MALAT1 was overexpressed in recurrent colorectal cancer (CRC) and metastatic sites in post-surgical patients. However, the upstream regulatory mechanism of MALAT1 is ...

    Authors: Xinnan Wu, Ruixiao Li, Qing Song, Chengcheng Zhang, Ru Jia, Zhifen Han, Lihong Zhou, Hua Sui, Xuan Liu, Huirong Zhu, Liu Yang, Yan Wang, Qing Ji and Qi Li
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:435

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2022 41:205

  9. Breast cancer (BC) is the most frequent malignant tumor in females and the 2nd most common cause of brain metastasis (BM), that are associated with a fatal prognosis. The increasing incidence from 10% up to 40...

    Authors: Simon Bernatz, Elena I. Ilina, Kavi Devraj, Patrick N. Harter, Klaus Mueller, Sascha Kleber, Yannick Braun, Cornelia Penski, Christoph Renner, Rashi Halder, Lukas Jennewein, Christine Solbach, Frits Thorsen, Bernhard C. Pestalozzi, Axel Mischo and Michel Mittelbronn
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:434
  10. Bladder cancer (BC) is a common urothelial malignancy, characterized by a high recurrence rate. The biology of bladder cancer is complex and needs to be deciphered. The latest evidence reveals the critical rol...

    Authors: Cornelia Braicu, Rares Buiga, Roxana Cojocneanu, Mihail Buse, Lajos Raduly, Laura Ancuta Pop, Sergiu Chira, Liviuta Budisan, Ancuta Jurj, Cristina Ciocan, Lorand Magdo, Alexandru Irimie, Florentin Dobrota, Bogdan Petrut and Ioana Berindan-Neagoe
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:433
  11. Inefficient T-cell access to the tumor microenvironment (TME) is among the causes of tumor immune-resistance. Previous evidence demonstrated that targeting CXCR4 improves anti-PD-1/PD-L1 efficacy reshaping TME...

    Authors: Crescenzo D’Alterio, Maria Buoncervello, Caterina Ieranò, Maria Napolitano, Luigi Portella, Giuseppina Rea, Antonio Barbieri, Antonio Luciano, Giosuè Scognamiglio, Fabiana Tatangelo, Anna Maria Anniciello, Mario Monaco, Ernesta Cavalcanti, Piera Maiolino, Giulia Romagnoli, Claudio Arra…
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:432
  12. Pancreatic cancer is one of the most lethal malignancies due to frequent late diagnosis, aggressive tumor growth and metastasis formation. Continuously raising incidence rates of pancreatic cancer and a lack o...

    Authors: Claudia M. Kowolik, Min Lin, Jun Xie, Larry E. Overman and David A. Horne
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:431
  13. miR-133a-3p has been recently discovered to be down-regulated in various human malignancies, including breast cancer, and reduced miR-133a-3p levels have been significantly associated with breast cancer cell g...

    Authors: Wanyue Shi, Tingting Tang, Xinping Li, Siwei Deng, Ruiyi Li, Yingshan Wang, Yifei Wang, Tiansong Xia, Yanfeng Zhang, Ke Zen, Liang Jin and Yi Pan
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:429
  14. BMP3 gene is often found hypermethylated and hence inactivated in several types of cancers including colorectal cancer (CRC), indicating that it has a suppressor role in carcinogenesis. Though BMP3 is a reliab...

    Authors: Jialing Wen, Xianglin Liu, Yan Qi, Feng Niu, Zhitong Niu, Wenjing Geng, Zhaowei Zou, Renli Huang, Jianping Wang and Hongzhi Zou
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:428
  15. A promising strategy to overcome the chemoresistance is the tumor blood vessel normalization, which restores the physiological perfusion and oxygenation of tumor vasculature. Thalidomide (Thal) has been shown ...

    Authors: Yanwei Shen, Shuting Li, Xin Wang, Mengying Wang, Qi Tian, Jiao Yang, Jichang Wang, Biyuan Wang, Peijun Liu and Jin Yang
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:427
  16. Polo-like kinase 3 (PLK3) has been documented as a tumor suppressor in several types of malignancies. However, the role of PLK3 in colorectal cancer (CRC) progression and glucose metabolism remains to be known.

    Authors: Baochi Ou, Hongze Sun, Jingkun Zhao, Zhuoqing Xu, Yuan Liu, Hao Feng and Zhihai Peng
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:426
  17. In the original publication of this article, [1] the affiliation for Katia Scotlandi needs to be revised, because the author prefers using its Italian name: Experimental Oncology Lab, Experimental Oncology Lab...

    Authors: Claudia Chiodoni, Maria Teresa Di Martino, Francesca Zazzeroni, Michele Caraglia, Massimo Donadelli, Stefania Meschini, Carlo Leonetti and Katia Scotlandi
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:425

    The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:128

  18. Merkel cell carcinomas (MCCs) are rare, aggressive, therapeutically-challenging skin tumours that are increasing in incidence and have poor survival rates. The majority are caused by genomic Merkel cell polyom...

    Authors: Lucia Cappabianca, Stefano Guadagni, Rita Maccarone, Michela Sebastiano, Alessandro Chiominto, Antonietta Rosella Farina and Andrew Reay Mackay
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:424
  19. Galectins are beta-galactose specific binding proteins. In human cancers, including hepatocellular carcinoma (HCC), galectin-1 (Gal-1) is often found to be overexpressed. In order to combat the dismal diagnosi...

    Authors: Zoe Leung, Frankie Chi Fat Ko, Sze Keong Tey, Ernest Man Lok Kwong, Xiaowen Mao, Bonnie Hei Man Liu, Angel Po Yee Ma, Yi Man Eva Fung, Chi-Ming Che, Danny Ka Ho Wong, Ching Lung Lai, Irene Oi-Lin Ng and Judy Wai Ping Yam
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:423
  20. Cancer-initiating cell (CIC), a functionally homogeneous stem-like cell population, is resonsible for driving the tumor maintenance and metastasis, and is a source of chemotherapy and radiation-therapy resista...

    Authors: Jinhua Wang, Yajing Xing, Yingying Wang, Yundong He, Liting Wang, Shihong Peng, Lianfang Yang, Jiuqing Xie, Xiaotao Li, Wenwei Qiu, Zhengfang Yi and Mingyao Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:422
  21. The monocyte chemoattractant protein-induced protein (MCPIP) family consists of 4 members (MCPIP1–4) encoded by the ZC3h12A-D genes, which are located at different loci. The common features of MCPIP proteins are ...

    Authors: Katarzyna Miekus, Jerzy Kotlinowski, Agata Lichawska-Cieslar, Janusz Rys and Jolanta Jura
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:421
  22. Glioblastoma is the most common and aggressive brain tumour in adults with a median overall survival of only 14 months after standard therapy with radiation therapy (IR) and temozolomide (TMZ). In a novel mult...

    Authors: Ina Patties, Sonja Kallendrusch, Lisa Böhme, Eva Kendzia, Henry Oppermann, Frank Gaunitz, Rolf-Dieter Kortmann and Annegret Glasow
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:420
  23. Until very few years ago, the oncology community dogmatically excluded any clinical potential for immunotherapy in controlling brain metastases. Therefore, despite the significant therapeutic efficacy of monoc...

    Authors: Anna Maria Di Giacomo, Monica Valente, Alfonso Cerase, Maria Fortunata Lofiego, Francesca Piazzini, Luana Calabrò, Elisabetta Gambale, Alessia Covre and Michele Maio
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:419
  24. An increasing number of studies have shown that long noncoding RNAs (lncRNAs) play essential roles in tumor initiation and progression. LncRNAs act as tumor promoters or suppressors by targeting specific genes...

    Authors: Kun Qiao, Shipeng Ning, Lin Wan, Hao Wu, Qin Wang, Xingda Zhang, Shouping Xu and Da Pang
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:418

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2020 39:154

  25. MEIS2 has been identified as one of the key transcription factors in the gene regulatory network in the development and pathogenesis of human cancers. Our study aims to identify the regulatory mechanisms of ME...

    Authors: Lei Guan, Ting Li, Nanping Ai, Wei Wang, Bing He, Yanxia Bai, Zhaocai Yu, Mingyue Li, Shanshan Dong, Qingge Zhu, Xiao Xiao Ding, Shiming Zhang, Ming li, Guangbo Tang, Xiaochun Xia, Jing Zhao…
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:417
  26. At the beginning of tumorigenesis, newly born cancer cells must successfully avoid attack by the immune system. Although most abnormal cells are efficiently identified and destroyed by the immune system, parti...

    Authors: Kotaro Saga, Jinhee Park, Keisuke Nimura, Norihiko Kawamura, Airi Ishibashi, Norio Nonomura and Yasufumi Kaneda
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:416
  27. In the original publication of this manuscript [1], Fig. 5E lower panel was incorrect due to an error in the preparation of these figures for publication. It was noticed that in the lower panel of Fig. 5E, one...

    Authors: Huiling Lai, Xuejiao Zhao, Yu Qin, Yi Ding, Ruqi Chen, Guannan Li, Marilyne Labrie, Zhiyong Ding, Jianfeng Zhou, Junbo Hu, Ding Ma, Yong Fang and Qinglei Gao
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:415

    The original article was published in Journal of Experimental & Clinical Cancer Research 2018 37:32

  28. Tamoxifen resistance presents a huge clinical challenge for breast cancer patients. An understanding of the mechanisms of tamoxifen resistance can guide development of efficient therapies to prevent drug resis...

    Authors: Fujun Li, Lixia Miao, Teng Xue, Hao Qin, Santanu Mondal, Paul R. Thompson, Scott A. Coonrod, Xiaoqiu Liu and Xuesen Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:414
  29. CyclinD1 is crucial for cell cycling and can regulate the expression of Dicer, a crucial regulator of microRNA maturation. However, little is known on how CyclinD1 regulates Dicer and miRNA expression, and the...

    Authors: Yongqiang Qi, Da Wang, Wenhua Huang, Bing Wang, Di Huang, Fei Xiong, Xiaoping Chen and Yongjun Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:413
  30. The transcription factor HOXD9 is one of the members of the HOX family, which plays an important role in neoplastic processes. However, the role of HOXD9 in the growth and metastasis of gastric cancer (GC) rem...

    Authors: Huiqiong Zhu, Weiyu Dai, Jiaying Li, Li Xiang, Xiaosheng Wu, Weimei Tang, Yaying Chen, Qiong Yang, Mengwei Liu, Yizhi Xiao, Wenjing Zhang, Jianjiao Lin, Jing Wang, Guangnan Liu, Yong Sun, Ping Jiang…
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:412
  31. Long non-coding RNA (lncRNA) HOXA transcript at the distal tip (HOTTIP), has been demonstrated to be a vital biomarker when evaluating the prognosis of multiple cancers. Nevertheless, the potential function of...

    Authors: Anquan Shang, Weiwei Wang, Chenzheng Gu, Chen Chen, Bingjie Zeng, Yibao Yang, Ping Ji, Junjun Sun, Junlu Wu, Wenying Lu, Zujun Sun and Dong Li
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:411
  32. UFM1 has been found to be involved in the regulation of tumor development. This study aims to clarify the role and potential molecular mechanisms of UFM1 in the invasion and metastasis of gastric cancer.

    Authors: Jian-Xian Lin, Xin-Sheng Xie, Xiong-Feng Weng, Sheng-Liang Qiu, Changhwan Yoon, Ning-Zi Lian, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Qi-Yue Chen, Long-Long Cao, Mi Lin, Ru-Hong Tu, Ying-Hong Yang, Chang-Ming Huang, Chao-Hui Zheng…
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:410

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2023 42:307

  33. ATPase associated with a variety of cellular activities (AAA ATPase) family members are closely linked to tumor formation and progression. However, their roles in hepatocellular carcinoma (HCC) largely remain ...

    Authors: Meng-Xuan Zhu, Chuan-Yuan Wei, Peng-Fei Zhang, Dong-Mei Gao, Jie Chen, Yan Zhao, Shuang-Shuang Dong and Bin-Bin Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:409

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2019 38:443

  34. Replication-competent oncolytic viruses (OVs) have been proven to be a potent anticancer weapon for clinical therapy. The preexisting neutralizing antibody in patients is a big challenge for oncolytic efficacy...

    Authors: Mao Xia, Dongjun Luo, Jie Dong, Meihong Zheng, Gang Meng, Junhua Wu and Jiwu Wei
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:408
  35. In the publication of this article [1], there are two corrections.

    Authors: Ming Tan, Qian Zhang, Xiaohong Yuan, Yuanzhong Chen and Yong Wu
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:407

    The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:308

  36. Iron, an indispensable element for life, is involved in all kinds of important physiological activities. Iron promotes cell growth and proliferation, but it also causes oxidative stress damage. The body has a ...

    Authors: Fang Wang, Huanhuan Lv, Bin Zhao, Liangfu Zhou, Shenghang Wang, Jie Luo, Junyu Liu and Peng Shang
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:406
  37. Skin cutaneous melanoma (SKCM) is the most lethal form of skin cancer and while incidence rates are declining for most cancers, they have been steadily rising for SKCM. Serine protease inhibitor, kunitz-type, ...

    Authors: Elena Gómez-Abenza, Sofía Ibáñez-Molero, Diana García-Moreno, Inmaculada Fuentes, Leonard I. Zon, Maria C. Mione, María L. Cayuela, Chiara Gabellini and Victoriano Mulero
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:405
  38. Metabolic reprogramming is an important characteristic of tumors. In the progression of pituitary adenomas (PA), abnormal glucose metabolism has been confirmed by us before. However, whether cholesterol metabo...

    Authors: Xiao Ding, Kexia Fan, Jintao Hu, Zhenle Zang, Shunli Zhang, Yin Zhang, Zhichao Lin, Xiangdong Pei, Xin Zheng, Feng Zhu, Hui Yang and Song Li
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:404
  39. T cells play important roles in anti-tumor immunity. Emerging evidence has revealed that distinct metabolic changes impact the activation and differentiation of T cells. Tailoring immune responses by manipulat...

    Authors: Zhongping Yin, Ling Bai, Wei Li, Tanlun Zeng, Huimin Tian and Jiuwei Cui
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:403
  40. Dihydroartemisinin (DHA) has been shown to exert anticancer activity through iron-dependent reactive oxygen species (ROS) generation, which is similar to ferroptosis, a novel form of cell death. However, wheth...

    Authors: Yibing Chen, Yanjun Mi, Xiaofei Zhang, Qian Ma, Yucen Song, Liwei Zhang, Dandan Wang, Jinliang Xing, Benxin Hou, Haolong Li, Huan Jin, Wei Du and Zhengzhi Zou
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:402
  41. Colon cancer is the second leading cancer worldwide. Recurrent disease and chemotherapeutic drug resistance are very common in the advanced stage of colon cancer. ATP-citrate lyase (ACLY), the first-step rate-...

    Authors: Jun Wen, Xuejie Min, Mengqin Shen, Qian Hua, Yuan Han, Li Zhao, Liu Liu, Gang Huang, Jianjun Liu and Xiaoping Zhao
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:401
  42. Neuroblastoma (NB) is one of the deadliest paediatric solid tumours due to its rapid proliferative characteristics. Amplified copies of MYCN are considered the most important marker for the prediction of tumou...

    Authors: Ping Jiang, Mao Huang, Weiwei Qi, Fenghua Wang, Tianyou Yang, Tianxiao Gao, Chuanghua Luo, Jing Deng, Zhonghan Yang, Ti Zhou, Yan Zou, Guoquan Gao and Xia Yang
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:400
  43. Radiotherapy (RT) is a highly effective multimodal nonsurgical treatment that is essential for patients with advanced colorectal cancer (CRC). Nevertheless, cell subpopulations displaying intrinsic radioresist...

    Authors: So-Yeon Park, Choong-Jae Lee, Jang-Hyun Choi, Jee-Heun Kim, Ji-Won Kim, Ji-Young Kim and Jeong-Seok Nam
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:399
  44. Growing evidences indicate that circular RNAs (circRNAs) play an important role in the regulation of biological behavior of tumor. We aim to explore the role of circRNA in glioma and elucidate how circRNA acts.

    Authors: Jiansheng Chen, Taoliang Chen, Yubo Zhu, Yan Li, Yuxuan Zhang, Yun Wang, Xiao Li, Xiaomi Xie, Jihui Wang, Min Huang, Xinlin Sun and Yiquan Ke
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:398
  45. Immune checkpoint inhibition and in particular anti-PD-1 immunotherapy have revolutionized the treatment of advanced melanoma. In this regard, higher tumoral PD-L1 protein (gene name: CD274) expression is associa...

    Authors: Alexander Thiem, Sonja Hesbacher, Hermann Kneitz, Teresa di Primio, Markus V. Heppt, Heike M. Hermanns, Matthias Goebeler, Svenja Meierjohann, Roland Houben and David Schrama
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:397
  46. Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in HCC treatment, less than 40% o...

    Authors: Yaojie Fu, Shanshan Liu, Shan Zeng and Hong Shen
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:396
  47. Long non-coding RNA plays a crucial role in the occurrence and progression of glioma. We aimed to explore the function of LINC00174 in cell proliferation, apoptosis, migration, invasion and glycolysis of gliom...

    Authors: Jian Shi, Yang Zhang, Bing Qin, Yongjie Wang and Xiangdong Zhu
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:395
  48. m6A modification has been proved to play an important role in many biological processes. METTL3 as the main methyltransferase for methylation process has been found to be upregulated in many cancers, including...

    Authors: Wen Peng, Jie Li, Ranran Chen, Qiou Gu, Peng Yang, Wenwei Qian, Dongjian Ji, Qingyuan Wang, Zhiyuan Zhang, Junwei Tang and Yueming Sun
    Citation: Journal of Experimental & Clinical Cancer Research 2019 38:393

Annual Journal Metrics

  • 2022 Citation Impact
    11.3 - 2-year Impact Factor
    11.5 - 5-year Impact Factor
    1.870 - SNIP (Source Normalized Impact per Paper)
    2.413 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    100 days submission to accept (Median)

    2023 Usage 
    3,003,080 downloads
    3,022 Altmetric mentions